This week's Bulls N' Bears profiled ASX runner is … Imugene. Its share price jumped more than 212 per cent to join other impressive companies including Krakatoa Resources, TechGen Metals and GreenTech Metals.
If billionaire “prospector” Mark Creasy has the Midas touch when it comes to divining lucrative mineral deposits, Paul Hopper just might be the man who wields the mythical rod of Asclepius - the Greek God of medicine - when it comes to the equally lucrative ASX-listed biotechnology space. By any measure Hopper has experienced success listing and developing biotech companies on the ASX – and the last year was a good one.
Cancer fighting biotech, Radiopharm Theranostics has gained access to a rare medical isotope from a Bill Gates start-up to accelerate the development of its pipeline of cancer treatment therapies. The company says “actinium-225” is a radioactive isotype that can be attached to a targeting antibody that will then selectively target and destroy cancerous tissue.
SPECIAL REPORT: Despite WA's history of innovative medical research, the state's medtech sector continues to grapple with outsider perceptions and its own commercial direction.
Ardiden has appointed Bradley Boyle as executive director and Michael Stares as general manager – Canadian operations. Mr Boyle was formerly a managing director of Triton Minerals.
